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Sum_ary The aim of this study was to find a procedure allowing estimation of individual pharmacokinetic
parameters for adnramvcin with minimal cost and disturbance for the patient. Twenty-five patients with breast
cancer were treated by short infusion of adriamycin at a dose of 12mgm-' week- (41 courses). Population
characteristics were determined on 15 randomly chosen courses (10 patients, group I) in order to define two
optimal sampling times (26mmn and 24h) and to perform Bayesian estimation on the remaining 26 courses (17
patients. group II). For patients of group II. Bayesian estimation (BE) associated with a reduced sub-optimal
sampling protocol (20min and 24h) was compared with maximum likelihood estimation (MLE), the classical
procedure. Regression analysis of clearance values obtained after BE versus MLE indicated a high correlation
coefficient (r=0.969) with the slope (a=0.991 +0.085) and the intercept (b=2.271 +4.810) close to I and 0
respectively. This original method is thus valid to measure accurately adnamycin clearance, it improves
patient comfort and can be used routinely.
Pharmacokinetic population studies have been developed in
recent years to describe intra- and interindividual variabilities
(Sheiner & Beal, 1981a). Among the available methods.
Bayesian estimation (BE) allows satisfactory model para-
meter estimation with a limited number of sampling points
and thus reduces hospitalisation time as well as cost of
pharmacokinetic studies (Sheiner et al., 1979). Such metho-
dological schemes associating BE with a population study
have been performed for several drugs (D'Argenio &
Khakmahd, 1983; Lacarelle et al., 1987; Vozeh & Steiner.
1987; Serre-Debeauvais et al., 1987) but few anticancer ones
(Iliadis et al., 1985; Favre et al., 1987). Moreover, sampling
points are generally chosen arbitrarily or sometimes by using
more sophisticated approaches like sensitivity functions or
stepwise linear regression (Ratain & Vogelzang, 1987). But
these approaches are not optimal, since they do not provide
maximal precision in model parameters.
Adriamycin (ADM) is a broad-spectrum antineoplastic
drug which is active against a wide variety of tumours.
Experimental studies have suggested that ADM
concentration-time product (area under the curve, AUC) is a
determinant factor for tumour cell lethality (Eichholtz-Wirth,
1980; Ritch et al., 1982). Robert et al. (1982) observed a
correlation between pharmacokinetic parameters and clinical
short-term response. Finally, according to Powis (1985),
AUC is the best pharmacokinetic parameter for predicting
anticancer pharmacodynamic events. As well as the relation-
ships between AUC and response, there is also pharmaco-
kinetic variability. For example, Rodvold et al. (1988)
reported a reduced systemic clearance (Cl) of ADM in the
obese. It is thus necessary to control this variability when
dosage regimen calculations are required. Nevertheless, for
breast cancer patients receiving regular ADM administ-
rations, it is difficult to determine AUC or Cl (Cl=dose
AUC) on the basis of the entire concentration-time curve as
this requires a prolonged hospitalisation time and several
blood samples. We applied a method of limited sampling
associated with BE to ADM pharmacokinetics. The study
was undertaken in a homogeneous group of 25 patients with
breast cancer receiving several courses of ADM (a total of
41 courses). It consisted of two complementary steps: 15
courses were used to determine population characteristics
and the optimal, limited sampling protocol (two points); the
remaining 26 were considered to validate the method. This
was done by comparing Cl values computed by using
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classical maximum likelihood estimation (MLE) and those
computed by BE with the limited sampling protocol.
Materials and methods
Patients
Twenty-five patients with advanced breast cancer (all
women: mean age 67.5 years. range 41-85) were treated by
ADM on the basis of weekly injections (12mgm 2 week ').
Included were 42% of patients with primary tumour only,
10% with primary and distal metastases, 38% with multi-
focal metastases and 10% with isolated metastases (liver and
bone). There was no concomitant irradiation. Cumulative
dose of ADM per patient was (mean, range) 372mg, 100-
600mg. Five patients had previously been treated by a
chemotherapy regimen including anthracyclines and the total
cumulative dose, including weekly ADM, was (mean, range)
640mg, 160-1,011mg; two other patients had received a
chemotherapy protocol without anthracyclines. All patients
had normal pretreatment serum bilirubin (5-17jmoll-1). In
all cases, ADM was given by a 5-min infusion through a
venous catheter. A complete pharmacokinetic study concern-
ing ADM given on a weekly schedule on the same patients
has been published (Frenay et al., 1988).
Analttical method
A complete pharmacokinetic profile was obtained for the
first injection in 25 patients and once a month in 10 of them,
i.e. in most cases at the 5th, 9th and 13th injections. Blood
samples were drawn 5, 20, 40mmn and 1, 2. 4, 8 and 24h
after the start of injection. As all patients were treated on an
outpatient basis, it was not possible to get blood samples for
more than the 24h. From these patients and their cycles, 41
concentration-time curves were obtained. Blood samples
were collected in EDTA tubes and immediately centrifuged.
Plasma was stored at -20-C until analysis (within 2 weeks).
ADM was quantified by HPLC. Extraction was performed
on Sep-Pak C18 cartnrdges (Millipore, Waters) as previously
described (Robert. 1980) with slight modifications: cartnrdges
were conditioned by successive elutions with 2ml methanol
and 5 ml phosphate buffer (Na2HPO4, 0.05 M; NaH2P04,
0.05 M; 2:1). One ml of plasma (patient or plasma for
standard curve) spiked with 50pi of internal standard
(daunorubicin, 1 nmolml -1) was passed through the car-
tridge, followed by I ml of phosphate buffer (discarded).
Drug material was eluted by 3ml of methanol in previously
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siliconated tubes. After drying (N2, 40-C), the residue was
diluted in 250pd of HPLC bufter, centrifuged for 10 min at
4 C, and injected into the HPLC system. Analysis was
performed on an HPLC column pBondapak phenyl
30mm x 0.4mm ID (Millipore, Waters) with a CH3CN-
formiate buffer (33.5/66.5), pH 4, at a flow rate of
2.5mlmin-I- Fluorescent detection was performed with a
spectrofluorimeter (Kontron SFM 25) at 4=470nm and
i,=600nm.
Pharmacokinetic study
By using MLE, all concentration-time curves were fitted to
an open two-compartment model expressed as a sum of
exponentials:
c(t)=A . e-at+B e-bt
where A and B (the coefficients) and a and b (the exponents)
are the model macroconstants allowing calculation of con-
centration c at time t. These macroconstants, evaluated by
MLE, constitute the reference values. Note that MLE is the
criterion defined by minimising the sum of squares of the
concentrations weighted by the model predictions, assuming
normality for measurement error with vanrance proportional
to the squared expected concentration value. This procedure
is sometimes called iteratively reweighted least squares
(Sheiner & Beal, 1985). The initial set of 41 cycles (25
patients) was randomly divided into two groups: one includ-
ing 15 cycles (10 patients, group I) was used to calculate
population characteristics by the standard two-stage method
(Sheiner & Beal, 1981a). Inter- and intra-individual variabili-
ties are both present in population studies; in order to
express the former, we randomly chose 10 subjects and, to
express the latter, five additional courses were drawn in four
of these 10 subjects. This was done to take into account
changes in the pharmacokinetic behaviour between two
successive courses, e.g. a possible time-dependence. The
other group of 26 cycles (17 subjects, group II) was used as
a test data set to evaluate the performance of BE associated
with a reduced sampling protocol.
First, population data allowed computation of an optimal
sampling time set to be used for all patients of group II. For
ethical reasons and improved patient comfort, we planned
only two sampling points, at least 5 min apart, during the
24h following the ADM administration. This calculation
was performed on the basis of D-optimality theory. Its main
characteristic is to guarantee a precise estimation of the
model pharmacokinetic parameters (the macroconstants) by
optimising a non-linear cost function (Bard, 1974; Launay &
Iliadis, 1988). The criterion value, i.e. the maximised cost
function value, is inversely proportional to the volume of the
confidence region for the parameter estimates (Atkinson &
Hunter, 1968); the higher its value is, the smaller the volume
is and the more precise the estimates are.
In fact, the set of two optimal samplnig times yielded by
the D-optimality criterion remains theoretical because these
times differ from the experimental ones. Thus, to choose the
available experimental sampling times closest to the theoreti-
cal ones, we compared the D-optimality criterion values
obtained for all experimental two time-point combinations.
Secondly, as population data are a priori information on
the ADM pharmacokinetic behaviour, they are used in the
BE criterion performed on the test data set (Iliadis et al.,
1985). All MLE and BE as well as optimal design calcula-
tions were performed on a desktop computer (Tektronix
4052) using APIS software (Iliadis, 1985; Launay & Iliadis,
1988). The parameters identified by MLE and BE are the
macroconstants from which Cl is computed (Wagner, 1975).
We selected Cl estimation since this parameter has the
greatest potential for clinical applications. It is also the most
useful parameter for the evaluation of an elimination
mechanism.
Statistics
Efficiency of BE with respect to MLE is studied on Cl. The
performance of Cl prediction was analysed according to the
suggestions of Sheiner & Beal (1981b). A correlation analysis
was done to confirm the prediction reliability of Bayesian
estimates with regard to maximum likelihood estimates.
Resuhts
ADM population data describing the mean behaviour (mean
parameters), interindividual variability (covariance and
correlation matrix) and residual intra-individual variability
(coefficient of variation of residual variability) are presented
in Table I. Because of the low residual variability (15%) and
its measurement error (10%), two compartment modelling is
a good description of the observed data. The coefficient of
variation of the exponents (a and b) was smaller than that of
the coefficients (A and B), indicating a low interindividual
variability for the slopes of the two phases. The low
correlation coefficients expressing covariances indicate that
there is no preferential relation between parameters. Figure I
shows the mean kinetic profile of ADM after a 20mg bolus
injection with its 68.3% confidence intervals expressing inter-
individual variability of concentrations in function of time.
Design optimisation with population data provided the
two 'theoretical' time points located at 26min and 24h,
corresponding to a critenron value of 35.743. Computation of
Table I Population pharmacokinetic parameters evaluated for 15 patients (group 1)
Macroconstants
Mean population parameters 00
A
7.058 x lo-2
B a
7.355 x 10-' 8.665
b
5.589 x 10-2
Coefficient of variation (%)
Covariance and correlation matrix
Coeffuicent of variation of residual variability= 1500
The macroconstants are the model parameters: A and B are the coefficients and a and b are the exponents. The covanrance-correlation
matrix is divided into three parts: the correlations between two parameters are in the upper triangle (1). They were computed from the
covariances which are written in the lower triangle (2). The variance of each parameter (squared standard deviation) is presented on the
diagonal of the matrix (3).ADRIAMYCIN CLEARANCE 91
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the D-optimality criterion for all experimental two time-
point combinations is summarised in Table II: the experi-
mental value closest to 35.743, the maximum, was 35.585,
corresponding to the 20min and 24h combination. The
20min sampling time was the most informative one as the
highest criterion values are in its column.
We therefore used the experimental sampling protocol of
20min and 24h to perform BE on the test data set (group II
data). Estimated macroconstants then served to compute
individual Cl values. The central question that arises was: is
it possible to predict reliable Cl values from two sampling
points, thus precluding the need for an entire concentration-
time curve? Computing bias and precision of Cl values
allowed evaluation ofpredictive performance of the Bayesian
method. Their mean values on the test set were respectively
1.86 and 7.81 1h-1, with associated 97.5% confidence inter-
vals of (- 1.26, 4.98) and (5.19, 9.79) respectively. We
concluded that bias was not significantly different from zero
(its confidence interval includes zero) and the positive sign
indicates that BE Cl is overestimated by about 1.861h-1.
The overestimation is not significant. We noted also that
precision of Cl estimates was low with respect to the
dispersion of Cl values in the population: the standard
deviation of BE Cl expressing interindividual variability,
computed on group II data, reached 29.851h-1. Thus the
ratio of this dispersion to the precision of BE Cl estimation
is 0.262; this means that the Bayesian procedure is discrimi-
native enough to distinguish subjects within members of the
same population.
Figure 2 presents regression analysis of Cl values obtained
after BE versus MLE ones. The correlation coefficient
(r=0.969) is high and differs significantly from zero
(P<0.001, d.f.=25). The estimated values of the slope
(a=0.991+0.085) and the intercept (b=2.271+4.810) are
close to 1 and 0 respectively, showing the statistical equiva-
lence between MLE and BE Cl values.
It is interesting to note that BE was able to predict
clearance values included within two extremes of 6.575 and
137.451h-i (a ratio of 1/20) with moderate relative errors of
TabW D-optimality criterion value for all combinations between
two experimental sampling times
5min 20min 20min Ih 2h 4h 8h
20min 34.933 - - - - -
40min 34.910 34.724 - - - -
lh 34-362 35.112 34.193 - - -
2h 34.298 35.149 34.302 33.034 -
4h 34.296 35.140 34.296 33.060 32.972 -
8h 34.317 35.157 34.349 33.220 33.108 33.013 -
24h 34.648 35-5 35.059 34.315 34.196 34.067 33.802
The computed theoretical value of the D-optimality criterion,
35.743, was obtained for 26min and 24h.
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21.2 and 9.9% respectively. Other than for the patient with
the highest relative error of 76.8%, bias never exceeded
25.9%.
Diwssco-
The present study develops a complete procedure to effi-
ciently estimate pharmacokinetic parameters with a minimal
clinical cost. Its main contribution lies in the choice of a
two-point sampling protocol guaranteeing a precise estima-
tion of the model pharmacokinetic parameters. The good
predictive performances reported indicate that Bayesian pro-
cedures should be developed for Cl prediction of ADM. The
two time-point protocol (20min, 24h) proved efficient but a
better estimation of the pharmacokinetic parameters should
be obtained with 26min and 24h, the theoretically most
informative sampling points, yiekling more accurate values
for new patients. In many clinical situations, determination
of ADM Cl may be relevant. For example, in hepatic
impairment, the relationship between the bilirubin level and
the degree of alteration in ADM pharmacokinetics is not
obvious (Kaye et al., 1985). It is thus diflicult to adjust the
ADM dose with regard to bilirubin level for a given patient.
The limited sampling procedure leads to easy estimation of
ADM Cl and could be used for monitoring of patients with
bepatic abnormalities. Besides, since ADM Cl is reduced in
obese patients (Rovold et al., 1988), its determination may
be justified in this category of patients; a limited sampling
procedure can be very useful as venous access is often
difficult in obese patients. The method developed could also
be of use for quicker estimations of AUC (Cl=dose/AUC),
while reducing the difficulties of trials. Moreover, the two-
point sampling protocol can be recalculated for periods
longer than 24h to take into account the part of the AUC
due to a late elimination phase. In this case, the protocol still
reduces the number of samplings while improving patient
comfort. Another limited sampling model has recently been
developed to esimate vinblastine AUC by using two time
points selected by a stepwise multiple regression analysis
(Ratain & Vogelzang, 1987). More recently, this team carried
out the same kind of study with amonafide (Ratain et al.,
1988). In agreement with these authors, we think that a
limited sampling procedure is of great clinical interest
because it suppresses the need for continuous hospitalisation
and minimises the number of venous punctions. This
approach is based on calculation of population character-
istics, thus showing the interest and need of interpatient
variability studies. We think that a reduced cost should lead
to a larger scale development of pharmacokinetic studies, a
better understanding of anticancer pharmacodynamics and
an optimisation of dosing.
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